FDA adds rare vision-loss risk to labels of all GLP-1 drugs
The gist
The FDA will add the risk of NAION, a rare eye condition, to all GLP-1 drug labels.
The warning covers popular weight-loss shots like Ozempic and Zepbound.
How it unfolded
- 2024A medical paper tied NAION to certain patients taking semaglutide, prompting FDA scientists to look into the problem.
- Jun 2025The European Medicines Agency's safety committee classed NAION as a very rare side effect of semaglutide, a conclusion concerning semaglutide specifically.
- Nov 9, 2026The FDA announced the risk of NAION will be added to the labeling of all GLP-1 drugs, a class including about a dozen medicines such as Ozempic, Wegovy, Zepbound and Mounjaro.
Key terms
- GLP-1 drugs
- A class of medications that activate the GLP-1 receptor, reducing blood sugar, appetite, and energy intake.
- NAION
- A non-inflammatory condition causing vision loss from insufficient blood supply to the front of the optic nerve.
- European Medicines Agency
- An EU agency responsible for evaluating and supervising pharmaceutical products.
Source: Wikipedia